Part I: Preventing & Reversing Chronic Migraine
Key Questions
- How do episodic migraine and chronic migraine disease differ from each other?
- What counts as a “headache day” when making a diagnosis of chronic migraine?
- Do people with chronic migraine experience special challenges and burdens?
- What are interictal symptoms, and how do they differ with chronic migraine?
- What comorbidities are associated with chronic migraine?
- What are the risk factors for progression from episodic to chronic migraine?
- What physiological changes occur in the brain as migraine becomes chronic?
- Is research underway to improve our understanding of migraine progression?
- Are there effective strategies for preventing progression to chronic migraine?
- Can a person with chronic migraine revert to an episodic pattern of attacks?
Interview Notes
- Richard B. Lipton, MD
- Montefiore Headache Centre
- International Classification of Headache Disorders Third Edition (ICHD-3)
- Study: “Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: Results of the American Migraine Prevalence and Prevention (AMPP) study”
- Article: “Understanding Research: What is the American Migraine Prevalence and Prevention (AMPP) Study and What We Have Learned From It?”
- Study: “Risk factors for migraine disease progression: a narrative review for a patient-centered approach”
- Study: “Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO study”
- Study: “Are we closer to achieving precision medicine for migraine treatment? A narrative review”
- Study: “Candesartan in migraine prevention: results from a retrospective real-world study”
Treatments Mentioned
- Angiotensin II receptor blockers (ARBs)
- Atogepant (Qulipta/Aquipta)
- Barbiturates
- Caffeine
- Candesartan
- Cognitive behavioral therapy (CBT)
- CGRP monoclonal antibodies (mAbs)
- Fiorinal
- Fioricet
- CGRP small-molecule receptor antagonists (gepants)
- Mindfulness
- Narcotics
- Neuromodulation devices
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- OnabotulinumtoxinA (Botox)
- Opioids
- Rimegepant (Nurtec ODT/Vydura)
- Topiramate (Topamax)
- Triptans
- Ubrogepant (Ubrelvy)
- Zavegepant (Zavzpret)
Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.
Richard B. Lipton, MD
Professor of Neurology & Director of the Montefiore Headache Center, and Director of the Division of Cognitive Aging and Dementia
Albert Einstein College of Medicine
Dr. Richard B. Lipton is an expert in headache and migraine management, as well as cognitive aging and dementia. He serves as the director of the Montefiore Headache Center and holds the prestigious Edwin S. Lowe chair in neurology at Albert Einstein University in New York. Internationally acclaimed for his contributions to headache diagnosis, classification, epidemiology, and treatment, Dr. Lipton has an impressive bibliography with 11 books and over 1,000 articles in indexed journals. His textbook, Headache in Clinical Practice, earned him the Medical Book Award from the British Medical Association.
He is past president of the American Headache Society (AHS), and is an associate editor for Cephalalgia: An International Journal of Headache. Additionally, he contributes to several other editorial boards, including for Neurology. His outstanding research has been recognized six times with the Harold G. Wolff Lecture Award from the AHS. Beyond neurology, Dr. Lipton is also a professor in psychiatry, behavioral sciences, epidemiology, and population health at the Albert Einstein College of Medicine.
For a limited time get up to 21% OFF all the 2025 interviews, videos, audio, transcripts, and more. Why upgrade?
- Can’t attend live? Watch anytime
- Prefer reading or listening? Get transcripts and audio
- Want to dive deeper? Explore the additional footage & resources
- Need ongoing support? Reference expert advice year-round
- Lifetime access to 2025, no annual fee
- Act now, early-bird offer ends March 19th!
Related Talks for: Day 2 (2025)
How Heavy Metals & Trace Elements Affect Migraine
Robert Bonakdar, MD
Are People With Migraine Having More Strokes & Heart Attacks?
Chia-Chun Chiang, MD
Global Guidelines for Acute Migraine Treatment
Simona Sacco, MD
The American Migraine Foundation (AMF) is a non-profit organization dedicated to the advancement of research and awareness surrounding migraine, a disabling condition that impacts more than 37 million men, women and children in the United States. The AMF was founded in 2010 to provide global access to information and resources for individuals with migraine as well as their family and friends.
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, and LinkedIn.
Noticing new symptoms? Struggling with Chronic Migraine? Looking for hope? Try these Learning Tracks to more to get the most out of your Summit experience.
